Wells Fargo & Company MN Acquires 7,587 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Wells Fargo & Company MN raised its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 61,867 shares of the company's stock after buying an additional 7,587 shares during the quarter. Wells Fargo & Company MN owned approximately 0.09% of Akero Therapeutics worth $1,721,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its position in Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock worth $3,662,000 after acquiring an additional 71,652 shares during the period. Exome Asset Management LLC purchased a new position in Akero Therapeutics in the 3rd quarter valued at $2,212,000. SG Americas Securities LLC increased its stake in Akero Therapeutics by 4,022.1% in the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company's stock valued at $16,636,000 after buying an additional 583,486 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Akero Therapeutics by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock worth $412,000 after buying an additional 1,446 shares during the last quarter. Finally, abrdn plc lifted its stake in shares of Akero Therapeutics by 118.7% in the 4th quarter. abrdn plc now owns 269,782 shares of the company's stock worth $7,505,000 after acquiring an additional 146,424 shares during the period.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AKRO shares. Citigroup increased their target price on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. HC Wainwright raised their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a report on Monday, March 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Canaccord Genuity Group raised their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Finally, UBS Group upped their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $76.29.

Akero Therapeutics Stock Down 0.8 %

NASDAQ AKRO traded down $0.36 on Thursday, hitting $45.26. 211,421 shares of the stock traded hands, compared to its average volume of 871,539. The company has a market capitalization of $3.60 billion, a P/E ratio of -12.07 and a beta of -0.18. The stock has a 50-day moving average of $41.80 and a 200 day moving average of $36.82. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Insider Transactions at Akero Therapeutics

In related news, insider Timothy Rolph sold 6,250 shares of the firm's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $41.03, for a total value of $256,437.50. Following the transaction, the insider now directly owns 169,721 shares in the company, valued at approximately $6,963,652.63. This trade represents a 3.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director G. Walmsley Graham acquired 91,309 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average cost of $44.75 per share, with a total value of $4,086,077.75. Following the transaction, the director now directly owns 1,091,309 shares in the company, valued at $48,836,077.75. The trade was a 9.13 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 227,458 shares of company stock valued at $10,271,361. Corporate insiders own 7.94% of the company's stock.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.